Home > Immunology Assays > Tumour Cell Killing
Immune cell-mediated tumour cell killingImmune cell-mediated killing of tumour cells is an important mode of action for immuno-oncology drugs. Celentyx provides assays using human primary immune cells, including purified CD8 T cells, gd T cells and NK cells, to quantify drug potency and efficacy. These assays can be performed using imaging or flow cytometry platforms.
Assays may be suitable for evaluating modulators of 4-1BB, BiTEs, CD3, CD27, CD28, CD40, CD40L, CD70, CD80, CD86, CTLA-4, Fas, FasL, JAK1, JAK2, JAK3, ICOS, ICOSL, IL-2R, IL-9R, IL-21R, LAG-3 OX40, OX40L, PD-1, PDL-1, PDL-2, STAT1, STAT3, STAT5, TIGIT, TIM-3, and others.
|
Further Immunology Assays
B Cells Haemolysis Testing Human Microglia Macrophages/Monocytes Neutrophils/Granulocytes Phagocytosis Assays Regulatory T Cells Spheroid Killing Assays Suppression Assays T Cell Activation Assays T Cell Exhaustion Assays Tumour infiltrating lymphocyte (TIL) and dissociated tumour cell assays |
Killing of human tumour cells by human PBMC; Imaging platformSpecific tumour cell killing was monitored over time by high-throughput confocal microscopy.
|
Killing of human tumour cells by human NK cells facilitated by a test monoclonal antibody; Flow cytometry platformTumour cells were cultured with NK cells either at rest (Tumor cells + NK cells) or following pre-treatment with increasing concentrations of a test therapeutic monoclonal antibody.
|
Antibody-dependent enhancement of tumour cell phagocytosisPhagocytosis of patient CLL cells by human monocyte-derived macrophages. Rituximab enhancement of CLL cell capture exhibited a ‘bell-shaped’ concentration-response emphasizing the importance of evaluating multiple concentrations.
|
|